Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Kaken Files Vascular Malformation Drug in Japan, Eyes FY2027 Approval
Kaken Pharmaceutical said on May 15 that it has filed for regulatory approval in Japan for KP-001 (serabelisib), its investigational treatment for refractory vascular malformations. The application is based on data from a domestic PIII trial, with the company aiming…
To read the full story
Related Article
- Kaken’s KP-001 Hits Goal in PIII Vascular Malformation Trial
November 11, 2025
BUSINESS
- Merck Biopharma Starts Japan PIII Trial of LH/FSH Combo
July 17, 2026
- Eisai’s Dayvigo Accepted for EMA Review
July 17, 2026
- AbbVie Files Maviret for Acute Hepatitis C
July 17, 2026
- FRONTEO, Santen Advance AI Drug Discovery Project to Second Phase
July 17, 2026
- Ferring’s Adstiladrin, Boehringer’s Jascayd Hit Market; Haizexin Due July 28
July 16, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…